Viridian Therapeutics, Inc. (NASDAQ:VRDN) Position Boosted by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 11.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 575,070 shares of the company's stock after purchasing an additional 58,857 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.73% of Viridian Therapeutics worth $11,024,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of VRDN. R Squared Ltd acquired a new stake in Viridian Therapeutics during the fourth quarter worth about $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Viridian Therapeutics during the 3rd quarter valued at approximately $149,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Viridian Therapeutics during the 3rd quarter worth $208,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Viridian Therapeutics by 17.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,997 shares of the company's stock worth $318,000 after buying an additional 2,036 shares during the period. Finally, Intech Investment Management LLC acquired a new stake in Viridian Therapeutics in the third quarter worth $422,000.

Wall Street Analyst Weigh In

VRDN has been the subject of several recent research reports. Royal Bank of Canada upped their price target on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the stock an "outperform" rating in a research report on Tuesday, December 17th. HC Wainwright reiterated a "buy" rating and set a $34.00 price objective on shares of Viridian Therapeutics in a research report on Monday, December 16th. Wells Fargo & Company reissued an "equal weight" rating and issued a $27.00 price objective (down from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. TD Cowen started coverage on Viridian Therapeutics in a research report on Monday, November 25th. They set a "buy" rating for the company. Finally, Needham & Company LLC reissued a "buy" rating and set a $38.00 price target on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat.com, Viridian Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $35.70.

Remove Ads

Viridian Therapeutics Price Performance

Shares of NASDAQ:VRDN traded down $0.66 on Tuesday, reaching $14.80. 754,994 shares of the company traded hands, compared to its average volume of 1,155,457. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. The stock has a market capitalization of $1.21 billion, a PE ratio of -3.43 and a beta of 1.05. The company's 50 day moving average is $16.98 and its 200-day moving average is $19.77. Viridian Therapeutics, Inc. has a fifty-two week low of $11.40 and a fifty-two week high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.24. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The firm had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.05 million. As a group, analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.